Physiomics uses Virtual Tumour and other industry standard technologies to predict the effects of cancer treatment regimes for the biopharma industry.

How can we help you?

Solve cancer drug development challenges

Optimise combination regimens, manage drug resistance, scale up from mouse to human, predict immune-oncology effects

Learn more

See our range of cancer modelling experience

Find out more about drug targets, drug types and cell lines where we have significant experience

Learn more

Learn about Virtual Tumour

Flexible in-silico cell-cycle based model combining PK and PD effects to predict cancer growth inhibition.

Learn more

Any other questions?

If you don’t see what you need here, please contact us by clicking on the link below.

Contact Us

News & publications

Dispatch of Annual Report and Shareholder Circular

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today posted to shareholders its Annual Report…

Dr Jim Millen interviewed by Proactive Investors

Dr Jim Millen, CEO of Physiomics, talks to Proactive Investors’ Andrew Scott about recent successes and the company’s future direction. Please click here to…

Final Results for the year ended 30 June 2018

Chairman and Chief Executive Officer’s Statement Introduction We are very pleased to report on a year when we generated the highest total income in the…

Contract award

Physiomics is delighted to announce that it has been awarded a contract by a new European biotech client.  The value of the contract is £55k…